Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
S0720: Adjuvant Therapy Based on Gene Expression in Stage IA and IB Non-Small Cell Lung Cancer
NCT00792701 · View on ClinicalTrials.gov ↗
Study Summary
RATIONALE: Drugs used in chemotherapy, such as gemcitabine and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving chemotherapy drugs after surgery may kill any tumor cells that remain after surgery. Sometimes, after surgery, the tumor may not need more treatment until it progresses. In this case, observation may be sufficient. PURPOSE: This phase II trial is studying how well giving gemcitabine together with cisplatin works in treating patients with stage I non-small cell lung cancer that was removed by surgery.
Conditions Studied
Interventions
- DRUG cisplatin
- DRUG gemcitabine hydrochloride
Study Locations (20)
California
- City of Hope Comprehensive Cancer Center — Duarte
- Tibotec Therapeutics - Division of Ortho Biotech Products, LP — Marysville
- Valley Medical Oncology Consultants - Pleasanton — Pleasanton
- Sutter Cancer Center at Roseville Medical Center — Roseville
- Sutter Cancer Center — Sacramento
- University of California Davis Cancer Center — Sacramento
- Tahoe Forest Cancer Center — Truckee
Illinois
- Saint Anthony's Hospital at Saint Anthony's Health Center — Alton
- Decatur Memorial Hospital Cancer Care Institute — Decatur
- Sherman Hospital — Elgin
- Regional Cancer Center at Memorial Medical Center — Springfield
Kansas
- Cancer Center of Kansas, PA - Chanute — Chanute
- Cancer Center of Kansas, PA - Dodge City — Dodge City
- Cancer Center of Kansas, PA - El Dorado — El Dorado
- Cancer Center of Kansas - Fort Scott — Fort Scott
Arkansas
- Hembree Mercy Cancer Center at St. Edward Mercy Medical Center — Fort Smith
Connecticut
- Saint Francis/Mount Sinai Regional Cancer Center at Saint Francis Hospital and Medical Center — Hartford
Georgia
- Northeast Georgia Medical Center — Gainesville
Hawaii
- Tripler Army Medical Center — Honolulu
Indiana
- St. Francis Hospital and Health Centers - Beech Grove Campus — Beech Grove
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 85 participants |
| Start Date | 2008-11 |
| Est. Completion | 2016-04 |
| Phase | Phase 2 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00792701
The ClinicalTrials.gov registry entry for NCT00792701 describes a study currently listed as completed. It is categorized as Phase 2, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 85 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is SWOG Cancer Research Network, which has 212 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 1 condition, with Lung Cancer appearing as the primary indexed condition, and to 2 interventions — of which cisplatin is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT00792701 reports 20 study locations spanning 8 distinct geographic areas — top geographies include California, Illinois, Kansas. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT00792701 about?
NCT00792701 is a clinical study titled "S0720: Adjuvant Therapy Based on Gene Expression in Stage IA and IB Non-Small Cell Lung Cancer". RATIONALE: Drugs used in chemotherapy, such as gemcitabine and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving chemotherapy drugs after surgery may kill any tumor cells that remain after surgery. Sometimes, af...
What is the current status of trial NCT00792701?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 85 participants. The study started on 2008-11. Estimated completion is 2016-04.
What conditions does trial NCT00792701 study?
This clinical trial studies the following conditions: Lung Cancer. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT00792701?
The interventions under investigation include: cisplatin (DRUG), gemcitabine hydrochloride (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT00792701?
This trial is sponsored by SWOG Cancer Research Network, which has 212 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT00792701 being conducted?
This trial has 20 study locations across Arkansas, California, Connecticut, Georgia, Hawaii. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.